



*STW*

# CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the U.S. Postal Service as first class mail on the date indicated below in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name of Person Mailing: BARBARA NOLAN

Signature: *Barbara Nolan* Date: *January 26, 2006*

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<b>Supplemental Information Disclosure Statement</b>  <b>Address to:</b> <b>Commissioner of Patents</b> <b>PO Box 1450</b> <b>Alexandria, VA 22313-1450</b>	<b>First Inventor</b>	<b>Jian Jeffrey Chen</b>
	<b>Application Number</b>	<b>10/722,703</b>
	<b>Filing Date</b>	<b>November 25, 2003</b>
	<b>Group Art Unit</b>	<b>1625</b>
	<b>Examiner</b>	<b>Robert J. Balls</b>
	<b>Attorney Docket No.</b>	<b>R0085D-CON</b>
	<b>Title</b>	<b>6-SUBSTITUTED PYRIDO-PYRIMIDINES</b>

Sir:

### Transmittal Letter for Supplemental Information Disclosure Statement

Applicants wish to bring to the attention of the Examiner references cited in the Chilean patent application that is a counterpart of the subject application. The attached Information Disclosure Statement is filed in compliance with 37 CFR §1.56, and the documents cited therein may be material to the patentability of the subject patent application.

- ☒ Attached with this Transmittal Letter are:
- (a) Information Disclosure Statement Form 1449;
  - (b) Copies of references cited;
  - (c) Certificate of Mailing;
  - (d) Return postcard.
- ☒ The Information Disclosure Statement is being submitted before the mailing date of the first Office Action. **Therefore, no fee is due under 37 CFR 1.97(b).**
- ☒ Additionally, the undersigned hereby certifies under 37 C.F.R. 1.97(e)(1) that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office on a counterpart foreign application not more than three (3) months prior to the filing of the Information Disclosure Statement. **Therefore, no fee is due.**

[X] Applicants believe that no fees are due. However, should this not be the case, the Commissioner is hereby authorized to charge any additional fees that may be required to Deposit Account No. 18-1700.

The Examiner is respectfully requested to consider these documents and to make them of record in the subject application.

Respectfully submitted,



Robert C. Hall  
Reg. No. 39,209  
Attorney for Applicants

Roche Palo Alto  
Patent Law Dept. M/S A2-250  
3431 Hillview Avenue  
Palo Alto, CA 94304  
Direct Phone (650) 354-7540

Date: January 25 2006



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT(S)**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/722,703
Filing Date	November 25, 2003
First Named Inventor	Jian Jeffrey Chen
Art Unit	1616
Examiner Name	Robert J. Balls
Attorney Docket Number	R0085C-CON

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	E1	WO 97/13771 A1	01/17/1997	Glaxo Group Limited		
	E2	WO 97/35539 A2,A3	10/02/1997	The DuPont Merck Pharmaceutical Company		
	E3	WO 98/46604 A1	10/22/1998	Abbott Laboratories		
	E4	WO 98/46605 A1	10/22/1998	Abbott Laboratories		
	E5	WO 99/65908	12/23/1999	Pfizer Products, Inc.		

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.** Doc. #134743